Peripheral Artery Disease Clinical Trial
— AMICOSOfficial title:
Peripheral Artery Disease (PAD) : Its Effects on Bone
Verified date | December 2022 |
Source | Centre Hospitalier Régional d'Orléans |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prevalence of PAD and osteoporosis (OP) both get higher with age. Clinical and epidemiologic evidence have showed an increased cardiovascular risk in OP and bone loss and fragility fractures in patient with cardiovascular disease. This study will examine the relationship between vascular disease in legs and sBMD and vBMD at trabecular and cortical sites and bone microarchitecture.
Status | Terminated |
Enrollment | 2 |
Est. completion date | May 19, 2021 |
Est. primary completion date | May 19, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - PAD patients defined by an Ankle brachial index < 0.9 - Written consent - Patient affiliated with a social security organism Exclusion Criteria: - Age < 18 years - Pregnancy or risk of pregnancy - Patients Under guardianship - Patient with known PAD who had been previously treated by surgery or endovascular pathway |
Country | Name | City | State |
---|---|---|---|
France | CHR d'ORLEANS | Orleans |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Régional d'Orléans |
France,
Breban S, Benhamou CL, Chappard C. Dual-energy X-ray absorptiometry assessment of tibial mid-third bone mineral density in young athletes. J Clin Densitom. 2009 Jan-Mar;12(1):22-7. doi: 10.1016/j.jocd.2008.10.009. Epub 2008 Dec 25. — View Citation
Collins TC, Ewing SK, Diem SJ, Taylor BC, Orwoll ES, Cummings SR, Strotmeyer ES, Ensrud KE; Osteoporotic Fractures in Men (MrOS) Study Group. Peripheral arterial disease is associated with higher rates of hip bone loss and increased fracture risk in older men. Circulation. 2009 May 5;119(17):2305-12. doi: 10.1161/CIRCULATIONAHA.108.820993. Epub 2009 Apr 20. — View Citation
Fehervari M, Sarkadi H, Krepuska M, Sotonyi P, Acsady G, Entz L, Lakatos P, Szeberin Z. Bone mineral density is associated with site-specific atherosclerosis in patients with severe peripheral artery disease. Calcif Tissue Int. 2013 Jul;93(1):55-61. doi: 10.1007/s00223-013-9727-5. Epub 2013 Apr 6. — View Citation
Gaudio A, Muratore F, Fiore V, Rapisarda R, Signorelli SS, Fiore CE. Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease. Osteoporos Int. 2015 Jun;26(6):1747-53. doi: 10.1007/s00198-015-3057-6. Epub 2015 Feb 12. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bone Mineral Density (BMD) volumic values at the tibias of PAD (Peripheral Artery Disease) patients | BMD volumic values are BMD volumetric bone mineral density (mg HA/cm3) | Day 0 | |
Secondary | Bone Mineral Density (BMD) measurement by DXA | Relations between areal BMD results (DXA) at the hip and lumbar spine and the ankle brachial index measured at the two legs. | Day 0 | |
Secondary | Correlation between microstructural parameters and ankle brachial index results | The following micro structural parameters assessed by HRpQCT at both tibias will be :
Dtrab : volumetric trabecular bone mineral density (mg HA/ cm3), Dinn : inner trabecular bone density (mg HA/cm3), Dmeta: metatrabecular bone density (mg HA/cm3), Dcort: volumetric cortical bone mineral density (mg HA/cm3), D100: total volumetric bone mineral density (mg HA/cm3), Tb.Th: trabecular thickness (mm), Tb.N: trabecular number (mm-1); Tb.Sp: trabecular separation (mm), Ct.Th: cortical thickness (mm); Tb1.NSD: intra-distribution individual separation (mm), BV / TV: trabecular bone volume (%). |
Day 0 | |
Secondary | Comparison between microstructural parameters at tibias | comparison between bone microarchitecture parameters at the tibia: the parameters will be compared between the most severely limb and the contralateral one. | Day 0 | |
Secondary | Correlation between Lipid and bone parameters | We will study the relation between lipidic and bone parameters. Potential correlations between on the one hand (lipid parameters: total and HDL-cholesterol, triglyceridemia, LDL-cholesterol calculation) and on the other hand bone parameters: vBMD volumetric bone mineral density (mg HA/cm3) Ct.BMD: cortical volumetric bone mineral density (mg/cm3); Tb.BMD: trabecular volumetric bone mineral density (mg HA/cm3) | Day 0 | |
Secondary | Percentage of densitometric osteoporotic patients | percentage of densitometric osteoporotic patients in the population | Day 0 | |
Secondary | Evaluation of risk of fracture | The risk of fracture at 10 years will be evaluate by the Fracture Risk Assessment Tool (FRAX) survey.
The FRAX® tool was developed by the then WHO Collaborating Centre for Metabolic Bone Diseases (1991-2010) at the University of Sheffield. It was launched in 2008 following approximately 10 years of meta-analyses of a variety of risk factors for osteoporotic fracture. Although not the only fracture prediction tool available, FRAX® is the only risk calculator which has been calibrated to rates of fracture and mortality per individual country and has been shown to identify a risk amenable to available treatments. |
Day 0 | |
Secondary | Evaluation of cardiovascular risk | Cardiovascular risk assessment using the SCORE tool (Systematic Coronary Risk Estimation).
Four levels of risk are defined: Very high cardiovascular risk = 10%; High risk, which includes subjects with major or particularly high risk factors (familial hypercholesterolemia, severe hypertension, etc.) and those with a score between 5 and 10%; Moderate risk, which concerns patients with a score between 1 and 5%; Low risk, which includes subjects with a score < 1%; |
Day 0 | |
Secondary | Correlation between microstructural parameters at tibias and radius | comparison between bone microarchitecture at the tibia and of the radius.
The following micro structural parameters assessed by HRpQCT at tibias and radius will be : Dtrab : volumetric trabecular bone mineral density (mg HA/ cm3), Dinn : inner trabecular bone density (mg HA/cm3), Dmeta: metatrabecular bone density (mg HA/cm3), Dcort: volumetric cortical bone mineral density (mg HA/cm3), D100: total volumetric bone mineral density (mg HA/cm3), Tb.Th: trabecular thickness (mm), Tb.N: trabecular number (mm-1); Tb.Sp: trabecular separation (mm), Ct.Th: cortical thickness (mm); Tb1.NSD: intra-distribution individual separation (mm), BV / TV: trabecular bone volume (%). |
Day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05712395 -
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
|
N/A | |
Active, not recruiting |
NCT04534257 -
Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore
|
N/A | |
Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Completed |
NCT02554266 -
Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
|
||
Completed |
NCT03921905 -
Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
|
||
Not yet recruiting |
NCT06369350 -
Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion
|
Early Phase 1 | |
Recruiting |
NCT04545268 -
Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance
|
N/A | |
Recruiting |
NCT02389023 -
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
|
N/A | |
Completed |
NCT02563535 -
Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia
|
Phase 4 | |
Completed |
NCT02539940 -
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
|
||
Completed |
NCT02542267 -
In-Stent Restenosis Post-Approval Study
|
N/A | |
Completed |
NCT02522884 -
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries
|
N/A | |
Completed |
NCT02145065 -
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
|
N/A | |
Completed |
NCT02228564 -
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02262949 -
A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System
|
N/A | |
Completed |
NCT01743872 -
Optical Imaging Measurement of Intravascular Solution Efficacy Trial
|
N/A | |
Recruiting |
NCT01424020 -
Walking Estimated Limitation Calculated by History - Study 2
|
Phase 4 | |
Active, not recruiting |
NCT01597453 -
NOR-SYS: The Norwegian Stroke in the Young Study
|
N/A |